OCT 15, 2020 8:04 PM PDT

WHO Data Suggests Remdesivir Has No Effect on COVID-19 Infections

WRITTEN BY: Carmen Leitch

While the study has not yet been peer-reviewed, an international consortium has come to the conclusion that the antiviral drug remdesivir has little or no benefit for hospitalized COVID-19 patients. The study followed 11,266 adult patients in 405 hospitals in thirty countries. Of this group, 2,750 were treated with remdesivir, 954 received hydroxychloroquine, others received a drug treatment used for HIV, and just over 4,000 others were not given any of these medications.

Colorized scanning electron micrograph of a cell showing morphological signs of apoptosis, infected with SARS-COV-2 virus particles (orange), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. / Credit: NIAID

The study assessed whether the drugs had any impact on mortality, when the patients needed ventilation, and the length of hospitalized patients' stays. In a statement, the World Health Organization (WHO) noted that the research did not assess whether any of these drugs have a preventive effect or might be useful for people that are not hospitalized.

This study confirms others that have indicated that hydroxychloroquinine has no beneficial effect.

Previous work has indicated that remdesivir can benefit patients that are on ventilators but not mild cases; in other words, the patient's condition has to be dire for remdesivir to work, according to other findings.

In a statement, the maker of remdesivir, GIlead, pushed back against WHO's data.

"The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of Veklury (remdesivir). We are concerned that the data from this open-label global trial have not undergone the rigorous review required to allow for constructive scientific discussion," Gilead said.

Earlier this year, the National Institutes of Health reported that a clinical trial involving patients hospitalized with COVID-19 and treated with remdesivir had shown positive results, but those benefits were modest. The trial suggested that patients on remdesivir would recover within around eleven days compared to fifteen days for people taking a placebo. The work also indicated that it may reduce mortality; 8.0 percent of people on remdesivir died, while 11.6 percent on placebo died. However, the trial was criticized for not including a diverse cohort of participants.

The NIH is currently conducting a study to investigate whether remdesivir plus interferon beta-1a is effective at treating COVID-19.

Sources: medRxiv, WHO, NIH

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAY 10, 2021
Coronavirus
Researchers Create a Vaccine For Multiple SARS Viruses, Including COVID-19 & Variants
MAY 10, 2021
Researchers Create a Vaccine For Multiple SARS Viruses, Including COVID-19 & Variants
The pandemic virus SARS-CoV-2 has changed the world in devastating ways, taking hundreds of thousands of lives & new var ...
JUN 17, 2021
Clinical & Molecular DX
A RADICA Approach to Viral Diagnostics
JUN 17, 2021
A RADICA Approach to Viral Diagnostics
  The COVID-19 pandemic has spurred a wave of new technologies for rapid viral diagnostics, given just how critical ...
JUN 29, 2021
Microbiology
Gut Fungi May Be an Untapped Reservoir of Antibiotics
JUN 29, 2021
Gut Fungi May Be an Untapped Reservoir of Antibiotics
Viruses are not the only microbes that can cause serious public health problems. Researchers have been warning about a p ...
JUL 15, 2021
Cell & Molecular Biology
Do Microbial Pathogens Have an Epigenetic Memory?
JUL 15, 2021
Do Microbial Pathogens Have an Epigenetic Memory?
Epigenetics are the parts of the genome that can affect the activity of genes but don't involve making changes to th ...
JUL 17, 2021
Microbiology
Fungi Can be a Healthy or Destructive Part of the Gut Microbiome
JUL 17, 2021
Fungi Can be a Healthy or Destructive Part of the Gut Microbiome
Scientists have been revealing the importance of gut bacteria; the huge numbers of bacterial species in our gastrointest ...
JUL 19, 2021
Microbiology
Engineering a Virus Trap
JUL 19, 2021
Engineering a Virus Trap
Viral infections are difficult to treat - antibiotics only work against bacteria - and there are few effective antibodie ...
Loading Comments...